Payment overview · 2025
General Payments
$386.18
20 reported records · 10 companies
Healthcare provider profile · identity verified
John David Bullock, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUMRALL, MS · NPI 1942217757
Verified facts
What the public records show
CMS Open Payments records show John David Bullock, MD received $386.18 in general payments during 2025 across 20 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.38 | 18.2% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $68.26 | 17.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.77 | 15.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $41.22 | 10.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.40 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $34.75 | 9.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.45 | 6.1% | 1 | 2025 |
| Tris Pharma Inc | Unresolved — no canonical attribution shown | $21.04 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.45 | 5.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.46 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $386.18 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $68.26 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $41.22 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.40 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $34.04 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.38 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.45 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| Dyanavel XR Normalized: dyanavel xr |
Drug | Tris Pharma Inc | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 109 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 27 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
27 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
116 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
109 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 905 | 186 |
| Atorvastatin Calcium | Atorvastatin Calcium | 750 | 162 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 737 | 166 |
| Pantoprazole Sodium | Pantoprazole Sodium | 619 | 134 |
| Irbesartan | Irbesartan | 521 | 103 |
| Losartan Potassium | Losartan Potassium | 457 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 428 | 84 |
| Omeprazole | Omeprazole | 426 | 93 |
| Gabapentin | Gabapentin | 363 | 103 |
| Metformin Hcl | Metformin Hcl | 363 | 83 |
| Famotidine | Famotidine | 337 | 77 |
| Sertraline Hcl | Sertraline Hcl | 298 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 288 | 81 |
| Potassium Chloride | Potassium Chloride | 271 | 55 |
| Lisinopril | Lisinopril | 228 | 58 |
| Montelukast Sodium | Montelukast Sodium | 227 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 220 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 55 |
| Meloxicam | Meloxicam | 216 | 61 |
| Carvedilol | Carvedilol | 202 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 202 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 51 |
| Glipizide Er | Glipizide | 190 | 38 |
| Allopurinol | Allopurinol | 175 | 35 |
| Furosemide | Furosemide | 175 | 44 |
| Trazodone Hcl | Trazodone Hcl | 173 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 165 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 163 | 34 |
| Valsartan | Valsartan | 147 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 44 |
| Spironolactone | Spironolactone | 136 | 32 |
| Buspirone Hcl | Buspirone Hcl | 127 | 25 |
| Glimepiride | Glimepiride | 126 | 27 |
| Metformin Hcl Er | Metformin Hcl | 125 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 123 | 18 |
| Mirtazapine | Mirtazapine | 120 | 20 |
| Ibandronate Sodium | Ibandronate Sodium | 117 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 18 |
| Jardiance | Empagliflozin | 116 | 21 |
| Bupropion Xl | Bupropion Hcl | 110 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 109 | 18 |
| Ozempic | Semaglutide | 109 | 22 |
| Simvastatin | Simvastatin | 108 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 24 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 105 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 20 |
| Ezetimibe | Ezetimibe | 99 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 92 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 86 | 19 |
| Alendronate Sodium | Alendronate Sodium | 82 | 20 |
| Pregabalin | Pregabalin | 80 | 22 |
| Chlorthalidone | Chlorthalidone | 77 | 23 |
| Eliquis | Apixaban | 77 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 18 |
| Donepezil Hcl | Donepezil Hcl | 72 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 22 |
| Aripiprazole | Aripiprazole | 66 | 16 |
| Baclofen | Baclofen | 64 | 14 |
| Celecoxib | Celecoxib | 63 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 62 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 59 | 20 |
| Lovastatin | Lovastatin | 59 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | suppressed |
| Fenofibrate | Fenofibrate | 57 | suppressed |
| Synthroid | Levothyroxine Sodium | 57 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 57 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 56 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 12 |
| Primidone | Primidone | 55 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 53 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 53 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 50 | 12 |
| Telmisartan | Telmisartan | 49 | 12 |
| Memantine Hcl | Memantine Hcl | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 45 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 12 |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Estradiol | Estradiol | 40 | suppressed |
| Ramipril | Ramipril | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Prednisone | Prednisone | 36 | 36 |
| Methenamine Hippurate | Methenamine Hippurate | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 34 | 14 |
| Ondansetron Odt | Ondansetron | 33 | 22 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 33 | suppressed |
| Linzess | Linaclotide | 32 | 11 |
| Meclizine Hcl | Meclizine Hcl | 32 | 16 |
| Tramadol Hcl | Tramadol Hcl | 32 | 18 |
| Alprazolam | Alprazolam | 30 | suppressed |
| Topiramate | Topiramate | 30 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 21 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | 11 |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 15 |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 23 |
| Mupirocin | Mupirocin | 24 | 12 |
| Glipizide | Glipizide | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 16 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | 11 |
| Indapamide | Indapamide | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tiazac | Diltiazem Hcl | 12 | suppressed |
| Topamax | Topiramate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $386.18 · 20 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Dyanavel XR, EVENITY, FARXIGA, Kerendia, MOUNJARO, Ozempic, QULIPTA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, VRAYLAR, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error